使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Hello everyone and thank you for joining the Amneal Q1 2025 earnings call. Good morning and welcome to the Amneal Pharmaceuticals first quarter 2025 earnings call. I'd now like to turn the call over to Am Neil's head of investor relations, Anthony DiMeo.
各位好,感謝大家參加 Amneal 2025 年第一季財報電話會議。早安,歡迎參加 Amneal Pharmaceuticals 2025 年第一季財報電話會議。現在我想把電話會議交給 Amneal 投資人關係主管 Anthony DiMeo。
Anthony Dimeo - Head of Investor Relations
Anthony Dimeo - Head of Investor Relations
Good morning and thank you for joining Amneal Pharmaceuticals first quarter 2025 earnings call. Today, we issued a press release report in Q1 results. The earnings press release and presentation are available at amneal.com
早安,感謝大家參加 Amneal Pharmaceuticals 2025 年第一季財報電話會議。今天我們發布了新聞稿,報告第一季業績。財報新聞稿與簡報可於 amneal.com 取得。
Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions are forward-looking statements that are based solely on information that is now available to us.
本次電話會議中所作之某些陳述,凡涉及非歷史事實之事項(包括但不限於管理層的展望或預測),均屬前瞻性陳述,且僅基於目前我們可取得的資訊。
Please see this section entitled Cautionary statements on forward-looking statements for factors that may impact future performance. We also discussed non-GAAP measures information on use of these measures and reconciliations to GAAP are in the earnings release and presentation.
請參閱「前瞻性陳述之警示聲明」一節,以了解可能影響未來表現的因素。我們亦將討論非 GAAP 衡量指標;關於使用這些指標的資訊以及與 GAAP 的調節,均載於財報新聞稿與簡報中。
On the call today are Chirag Patel and Chintu Patel, co-founders and co-CEOs. Taos Konidaris, Chief Financial Officer; our commercial leaders, Andrew Boyer for Affordable Medicines, Joe Renda for Specialty, and Jason Daly, Chief Legal Officer. I will now hand the call over to Chirag.
今天與會者包括共同創辦人暨共同執行長 Chirag Patel 與 Chintu Patel。財務長 Taos Konidaris;我們的商業團隊主管:Affordable Medicines 事業的 Andrew Boyer、Specialty 事業的 Joe Renda,以及法務長 Jason Daly。現在我把電話會議交給 Chirag。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you, Anthony. Good morning, everyone. In Q1, we delivered another quarter of strong performance and continued growth driven by the successful execution of our strategy. Q1 revenues of $695 million grew 5% and adjusted a bit down $170 million grew 12%.
謝謝你,Anthony。各位早安。第一季我們再度交出強勁表現並持續成長,主要來自我們成功執行策略。第一季營收 6.95 億美元,成長 5%;調整後 EBITDA 為 1.70 億美元,成長 12%。
Over the years, we have made deliberate decisions and investments across our business and delivered on our commitments. Over time and through market cycles, we have differentiated our me from our peers by delivering sustainable growth, even by our leadership and quality, innovation and execution.
多年來,我們在整個業務中做出審慎的決策與投資,並兌現承諾。隨著時間推移並歷經市場循環,我們透過可持續的成長使自己有別於同業,並以領導力與品質、創新與執行力脫穎而出。
Today, Amneal is in as strong a position as ever. We are embarking on our next phase of growth with momentum and confidence in our ability to deliver on our goals in 2025 and beyond. Big picture, Amneal is a trusted leader in an essential industry providing millions of Americans with access to affordable and innovative treatments.
今天,Amneal 的定位比以往任何時候都更強。我們正以動能邁入下一階段的成長,並對於在 2025 年及未來達成目標的能力充滿信心。從大方向來看,Amneal 是關鍵產業中值得信賴的領導者,為數以百萬計的美國人提供可負擔且具創新的治療選擇。
Each year, we fill over scr162 million pts for American patients. Amneal has one of the largest US pharmaceutical manufacturing footprints in the industry.
每年我們為美國病患配發超過 scr162 百萬張處方。Amneal 擁有業界規模最大的美國製藥製造據點之一。
With a broad portfolio of over 280 products over 150 of our medicines are made in the United States, from antibiotics, antivirals, to medicines that treat Alzheimer's, cancer, Parkinson's disease. What a meal made in America isn't just a label. It's been a cornerstone of our strategy since our founding in 2002 in Paterson, New Jersey.
我們擁有超過 280 項產品的廣泛產品組合,其中超過 150 種藥品在美國製造,涵蓋抗生素、抗病毒藥物,以及治療阿茲海默症、癌症、帕金森氏症等藥物。「Amneal 美國製造」不只是標籤。自 2002 年我們在新澤西州帕特森創立以來,這一直是我們策略的基石。
Let me now walk you through the key areas of our business. First, in our specialty segment, the launch of Cracks on for Parkinson's disease continues to exceed expectations in its first year of commercialization. market uptake has been strong, with market share already surpassing 1% and on track to reach over 3% by end of this year.
接下來我將帶各位了解我們業務的關鍵領域。首先,在我們的 Specialty(專科)事業中,用於帕金森氏症的 Cracks on 上市後第一年的商業化表現持續超出預期。市場採用強勁,市占率已超過 1%,並有望在今年底前達到 3% 以上。
We have received remarkable feedback from patients and providers as one key opinion leader who is also a patient, shared the following. Crexon has made me feel and move tremendously better compared to write. I have concrete examples of how Crexon has changed my life. It has made a huge difference.
我們從病患與醫療提供者那裡收到非常正面的回饋;其中一位同時也是病患的關鍵意見領袖分享如下:相較於 write,Crexon 讓我感覺與行動能力大幅改善。我有具體例子可以說明 Crexon 如何改變了我的生活。它帶來了巨大的差異。
In addition, we are pleased with the continued progress and momentum in expanding market access. This year so far, Freon has been added to several major insurance plans, including the Veteran Administration, United Healthcare, CVS Health, and Cigna commercial.
此外,我們也對於持續推進並加速擴大市場准入的進展感到滿意。截至今年目前為止,Freon 已被納入多個主要保險計畫,包括退伍軍人事務部(Veteran Administration)、United Healthcare、CVS Health,以及 Cigna 的商業保險。
This doubles the total US coverage from approximately 30% at the end of 2024 to approximately 60% of US covered lives today. To put that in perspective, Exxon has achieved in six months that took years to accomplish in market excess coverage.
這使美國總覆蓋率由 2024 年底約 30% 提升至目前約 60% 的受保人群。換個角度看,Exxon 在六個月內達成的市場准入覆蓋成果,過去往往需要數年才能完成。
We are highly confident in achieving US peak sales of $3,300million to 500 million. On. Overall, we are focused on expanding our specialty branded portfolio over time. Next, with the anticipated launch of our DHE autoinjector later this year.
我們對於在美國達成 3.3 億至 5 億美元的峰值銷售額非常有信心。整體而言,我們專注於隨時間擴大我們的專科品牌產品組合。接下來,預計於今年稍晚推出我們的 DHE 自動注射器。
Second, in GDP ones, we continue to advance our partnership with MTSA in the weight loss and obesity space, which represents a new integrated business model to drive innovation at scale in GLP ones. Matara is rapidly advancing its pipeline of ultra long acting injectable and oral candidates.
第二,在 GLP-1 方面,我們持續推進與 MTSA 在減重與肥胖領域的合作,這代表一種新的整合式商業模式,以在 GLP-1 領域規模化推動創新。Matara 正快速推進其超長效注射劑與口服候選藥物的研發管線。
As they have shared, Matara's lead program, MAT 0971, a monthly ultralong acting injectable, is expected to deliver phase 2B trial results mid-year. Emil is Master's preferred global supplier across the United States, Europe, and other markets. Also, Ee will commercialize their products in 20 emerging markets, including India.
如其所分享,Matara 的領先計畫 MAT 0971(每月一次的超長效注射劑)預計將於年中公布第 2b 期試驗結果。Amneal 是 Matara 在美國、歐洲及其他市場的首選全球供應商。此外,我們也將在包含印度在內的 20 個新興市場商業化其產品。
To support this plan, we are leveraging our existing infrastructure while constructing a high-volume peptide manufacturing facility and an advanced sterile fill and finish production facility.
為支持此計畫,我們在運用既有基礎設施的同時,正興建一座高產量胜肽製造設施,以及一座先進的無菌充填與成品製程(fill and finish)生產設施。
Over time we expect GDP ones will be a long-term growth driver for a new with three avenues of value creation. First and foremost, our collaboration with Matsara. Second, potential CMO offerings for other large companies, and lastly, manufacturing capacity we can provide for generic weight loss therapies globally.
長期而言,我們預期 GLP-1 將成為 Amneal 的長期成長動能,並透過三條途徑創造價值。第一且最重要的是,我們與 Matsara 的合作。第二,為其他大型公司提供潛在的 CMO(委託製造)服務。
Third, in our affordable medicine segment, which includes retail generics, injectables, and biosimilars, growth continues to be driven by our diversified, complex portfolio and new launches. In particular, our injectables portfolio is expanding.
第三,在我們的 Affordable Medicines(可負擔藥品)事業(包含零售學名藥、注射劑與生物相似藥)中,成長持續由我們多元化、複雜的產品組合與新產品上市所帶動。尤其是,我們的注射劑產品組合正在擴大。
Last month we launched Bruzu, which is our fourth 55B2 injectable launch over the last year. These ready to use solutions improve hospital efficiency by eliminating medication preparation steps and have unique reimbursement coding for hospitals.
上個月我們推出 Bruzu,這是過去一年內我們第 4 個 55B2 注射劑上市產品。這些即用型(ready-to-use)溶液可免除藥品調製步驟、提升醫院效率,並具備醫院端獨特的給付編碼。
Fourth, turning to biosimilars, this represents the next major wave of affordable medicines in the United States. According to an IQIA report, more than 100 biologics will lose exclusivity over the next decade. Yet only 10% have biosimilar in development. Biosimilars for the remaining 90% could save approximately $189 billion over 10 years.
第四,談到生物相似藥,這代表美國可負擔藥品的下一波重大浪潮。根據 IQIA 報告,未來十年將有超過 100 種生物製劑失去獨占權。然而,只有 10% 有生物相似藥正在開發中。其餘 90% 的生物相似藥若能推出,十年內可節省約 1,890 億美元。
For patients, biosimilars improve affordability and access to essential therapies. For EU, they represent a compelling long-term growth opportunity that we are well positioned to lead. Today our strategic focus has been in licensing our biosimilar portfolio and establishing a commercial platform.
對患者而言,生物相似藥可提升基本治療的可負擔性與可近性。對歐盟而言,這代表一項極具吸引力的長期成長機會,而我們具備領先的有利條件。目前,我們的策略重點在於授權我們的生物相似藥產品組合並建立商業化平台。
In 2024, our first three biosimilars generated $125 million revenue. In addition, we have expanded our pipeline with regulatory applications for five additional biosimilars being filed this year. By 2027, we expect to have six biosimilars on the market across eight product presentations. Our strategic goal is to be vertically integrated in biosimilars and leverage our proven ability and expertise to develop, manufacture, and commercialize complex biopharmaceuticals at scale.
2024 年,我們首三項生物相似藥創造了 1.25 億美元營收。此外,我們已擴充研發管線,今年將提交另外五項生物相似藥的法規申請。到 2027 年,我們預期將有六項生物相似藥上市,涵蓋八種產品規格/劑型呈現。我們的策略目標是在生物相似藥領域達成垂直整合,並運用我們已證實的能力與專業,在規模化條件下開發、製造並商業化複雜生物製藥產品。
Finally, growth in our healthcare segment continues to be driven by new launches across these channels distribution, government, and UNIDOs. We expect healthcare revenue to reach over $900 million by 2027. This business adds stability and diversification to Amneal's portfolio.
最後,我們醫療保健事業部的成長仍由這些通路的新產品上市所帶動:經銷、政府與 UNIDO。我們預期到 2027 年醫療保健營收將超過 9 億美元。此業務為 Amneal 的產品組合帶來穩定性與多元化。
In summary, Amneal has diverse array of growth drivers that enhance our competitive differentiation, drive sustainable value creation, and improve access and care for patients. Our strategic focus and long-term investments have been intentional and thoughtful. We could not be more excited about what the future holds as we advance our vision to be America's number one affordable medicines company. I will now turn it over to Chintu.
總結而言,Amneal 擁有多元的成長動能,可強化我們的競爭差異化、推動可持續的價值創造,並改善患者的可近性與照護。我們的策略聚焦與長期投資一直是有意識且審慎規劃的。隨著我們推進願景、成為美國第一的平價藥品公司,我們對未來充滿期待。接下來我將交給 Chintu。
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Thank you, Chirag, and good morning, everyone. Let me begin by expressing my deep appreciation to our Amneal team. The passion and commitment continue to drive forward as a purpose-driven company focused on innovation, execution, and value creation.
謝謝你,Chirag,各位早安。首先,我要對我們 Amneal 團隊表達由衷的感謝。作為一家以使命為導向、聚焦創新、執行與價值創造的公司,大家的熱情與承諾持續推動我們向前。
This morning, I will provide an update on our strategic priorities across operations, innovation, and our portfolio. First, on operations, our global high quality manufacturing infrastructure remains a key differentiator.
今天早上,我將就我們在營運、創新與產品組合方面的策略優先事項提供最新進展。首先在營運方面,我們全球高品質的製造基礎設施仍是關鍵差異化優勢。
Continues to be recognized for its teary quality track record and operational excellence. We are investing in digitization, automation, and AI technologies across our network to drive operational efficiency and our trusted quality and customer service reputation.
我們持續因其一流的品質紀錄與卓越營運而獲得肯定。我們正於整個網路投資數位化、自動化與 AI 技術,以提升營運效率,並鞏固我們在品質可信度與客戶服務方面的聲譽。
This foundation position positions as well to launch new products, help address drug shortages in the market and serve more patients. AI has a robust and diverse manufacturing footprint across the US, India, and Ireland. In the US, our extensive manufacturing infrastructure and capabilities are the foundation of our leadership position.
這項基礎也使我們具備良好條件推出新產品、協助因應市場藥品短缺,並服務更多患者。Amneal 在美國、印度與愛爾蘭擁有強健且多元的製造佈局。在美國,我們廣泛的製造基礎設施與能力是我們領導地位的根基。
We are one of the largest domestic pharmaceutical manufacturing footprints. In the industry as we produce many of our generics and specialty products, including Hexon in the US. Over the years we have built deep pharmaceutical manufacturing expertise across a wide range of dosage forms in the US, from oral solids to highly complex formulations.
我們擁有國內規模最大的製藥製造佈局之一。在產業中,我們於美國生產多項學名藥與專科產品,包括 Hexon。多年來,我們在美國建立了涵蓋多種劑型的深厚製藥製造專業,從口服固體到高度複雜的配方。
We have seven USFDA approved manufacturing facilities across 4 sites capable of making oral solids, liquids, topicals, transdermal patches, and nasal spray dosage forms with excess capacity to meet market needs. M is proud of its Made in America heritage, which is a competitive advantage and a core part of our strategy.
我們在 4 個據點擁有 7 座美國 FDA 核准的製造設施,可生產口服固體、液體、外用製劑、透皮貼片與鼻噴劑等劑型,且具備多餘產能以滿足市場需求。Amneal 以「美國製造」的傳承為榮,這是競爭優勢,也是我們策略的核心之一。
Turning to innovation, we are pleased with the progress of Cracks in the first six months of launch with strong KPI's across the board. The product is engineered for rapid onset and extended efficacy, delivering more good on time with fewer doses for Parkinson's patients. At the American Academy of Neurology meeting last month, our team shared new data from our phase 3 study showing significant improvements in sleep quality for patients on.
談到創新,我們對 Cracks 上市前六個月的進展感到滿意,各項 KPI 表現強勁。該產品經設計可快速起效並延長療效,讓帕金森氏症患者以更少的劑量獲得更準時、更佳的效果。在上月的美國神經學學會年會上,我們團隊分享了第三期研究的新數據,顯示患者的睡眠品質有顯著改善。
In particular, sleep disturbances affect up to 80% of PD patients. Further, our open label phase 4 study is underway to generate additional real world evidence. With robust early adoption and strong feedback from the neurology community and patients cracks on this po to become the leading branded product for Parkinson's disease.
特別是,睡眠障礙影響多達 80% 的帕金森氏症(PD)患者。此外,我們的開放標籤第四期研究正在進行中,以產出更多真實世界證據。憑藉早期採用動能強勁,以及神經科社群與患者的正面回饋,Cracks 有望成為帕金森氏症領域的領先品牌產品。
Next in our specialty pipeline is the DHE autoinjector for migraine and cluster headache. Our goal date is coming up this month. The innovative presentation of a well-known molecule was developed and will be manufactured in-house.
接下來,我們專科研發管線中的產品是用於偏頭痛與叢集性頭痛的 DHE 自動注射器。我們的目標日期就在本月。這項將知名分子以創新方式呈現的產品已完成開發,並將由我們自製生產。
The first and only DHE autoinjector is intended to help patients avoid emergency room visits during these painful headache episodes. We look to launch this product later this year and see the DHE autoinjector as a 50million to 100 million pixels.
首款且目前唯一的 DHE 自動注射器,旨在協助患者在這些疼痛的頭痛發作期間避免前往急診。我們預計於今年稍晚推出此產品,並將 DHE 自動注射器視為可帶來 5,000 萬至 1 億美元的機會。
In addition, our strategic partnership with MTSA in the GLP1 space is progressing as planned. As part of this collaboration, we are building two new manufacturing facilities, one for peptide drug substance production and another for advanced sterile field finish manufacturing. These facilities will enable high volume production as am serves as Amneal's preferred global supplier and will support large scale GLP-1 commercialization.
此外,我們與 MTSA 在 GLP-1 領域的策略合作正按計畫推進。作為合作的一部分,我們正在興建兩座新製造設施,一座用於胜肽藥物原料(drug substance)生產,另一座用於先進無菌充填與成品製造(fill-finish)。這些設施將支援高產量生產;MTSA 將作為 Amneal 的首選全球供應商,並支援 GLP-1 的大規模商業化。
If this collaboration exemplifies how we are leveraging our strong core competencies in R&D and complex manufacturing to live in high growth therapeutic areas like GLP ones. On our complex genetics portfolio. Each year we expect to launch 20 to 30 new products. We have launched eight new products so far in 2025.
這項合作正體現我們如何運用在研發與複雜製造方面的核心優勢,切入 GLP-1 等高成長治療領域。在我們的複雜學名藥產品組合方面,我們預期每年推出 20 至 30 項新產品。截至 2025 年目前為止,我們已推出 8 項新產品。
Later this year, we have several key complex product launches, including ophthalmic suspension and respirator injection. Overall, we have 81 ADA's pending approval, of which 65% are non-oral solids and 47 products in development, of which 96% are non-oral solids. We continue to prioritize within our R&D portfolio and allocate investment towards higher growth areas like specialty brands, injectables, and biosimilars over time.
今年稍晚,我們將有數項關鍵的複雜產品上市,包括眼科懸浮液與呼吸用注射劑。整體而言,我們有 81 件 ANDA 待核准,其中 65% 為非口服固體;另有 47 項產品在開發中,其中 96% 為非口服固體。我們持續在研發產品組合中進行優先順序調整,並逐步將投資配置至成長性更高的領域,如專科品牌、注射劑與生物相似藥。
In injectables we launched 12 new products in 2024 and expect to launch over 10 new injectables in 2025. In particular, we have launched 4 new 552 injectables over the last year, which is a new growth vector for our business. In April we launched Bruzo, our first 552 injectable.
在注射劑方面,我們於 2024 年推出 12 項新產品,並預期於 2025 年推出超過 10 項新注射劑。特別是,過去一年我們已推出 4 項 505(b)(2) 注射劑,這為我們的業務帶來新的成長動能。4 月我們推出 Bruzo,這是我們第一項 505(b)(2) 注射劑。
In addition, we have 10 to 12 more 552 injectables in development. Other complex injectable R&D programs, including microspheres, liposoms, and drug device combinations continue to progress well. Amneal is well positioned to be a leader in the injectable space in the coming years with a robust manufacturing footprint, deep scientific capabilities, and expanding portfolio in biosimilar.
此外,我們另有 10 至 12 項 505(b)(2) 注射劑正在開發中。其他複雜注射劑研發計畫(包括微球、脂質體與藥械組合)也持續順利推進。憑藉強健的製造佈局、深厚的科學能力,以及在生物相似藥方面持續擴大的產品組合,Amneal 在未來幾年具備成為注射劑領域領導者的良好條件。
We see a significant market potential given the upcoming wave of LOEs for biologics and the clear opportunity for AI to establish a leadership position in the space. This year we are filing our next five biosimilar pipeline candidates with launches targeted for 2026 and 2027. The BLA filings for two biosimilars were submitted with gold dates in quarter 4.
鑑於生物製劑即將迎來一波專利到期(LOE),以及 AI 在此領域建立領導地位的明確機會,我們看到了可觀的市場潛力。今年我們將提交下一批五個生物相似藥管線候選產品的申請,目標於 2026 年與 2027 年上市。兩項生物相似藥的 BLA 申請已提交,黃金日期落在第 4 季度。
Next, the supplemental BLA filings for pack field grassing OBI and autoinjector is expected in the 3rd quarter, followed by the BLA filings for biosimilar Zolar set for quarter 4. We look to expand our biosimilar portfolio and be vertically integrated over time.
接下來,針對 OBI 與自動注射器的補充 BLA 申請預計在第 3 季度提交,之後是生物相似藥 Zolar 的 BLA 申請,預計在第 4 季度提交。我們希望擴大生物相似藥產品組合,並隨時間推進垂直整合。
In summary, we have continued our strong operational momentum and execution in 2025. Our strategic focus on innovation, quality, and manufacturing excellence for sustainable growth and leadership across our business. Thank you. And with that I will hand it over to Tasos.
總結來說,我們在 2025 年持續保持強勁的營運動能與執行力。我們的策略重點聚焦於創新、品質與製造卓越,以實現可持續成長,並在各項業務中取得領導地位。謝謝。接下來我把時間交給 Tasos。
Tasos Konidaris - Chief Financial Officer, Executive Vice President
Tasos Konidaris - Chief Financial Officer, Executive Vice President
Thank you. Good morning, everyone. In the first quarter we saw continued broad-based growth across our three segments. Excellent uptake of cream and new product launches that further enhance our growth profile and diversification.
謝謝。各位早安。第一季我們看到三大事業部均持續呈現廣泛的成長。乳膏產品的優異放量,以及新產品上市,進一步強化了我們的成長輪廓與多元化。
As a result, we're incredibly proud of our global teams for delivering growth of 5% in revenue, 12% in adjusted EBITDA, and 50% growth in adjusted EPS. Our first cover our Q1 results in more detail, then 000 tariffs, and finally affirm our 2025 fully guidance.
因此,我們為全球團隊感到非常自豪:營收成長 5%、調整後 EBITDA 成長 12%,以及調整後 EPS 成長 50%。我將先更詳細說明我們第一季的業績,接著談關稅,最後重申我們 2025 年全年指引。
In the first quarter of 2025, total net revenues of $695 million to 5% in line with our expectations. Q1, affordable medicines revenue of $415 million grew by $23 million for 6%, and new products launched in 2024 and 2025 added $41 million.
2025 年第一季,總淨營收為 6.95 億美元,年增 5%,符合我們的預期。第一季,平價藥品(affordable medicines)營收為 4.15 億美元,增加 2,300 萬美元、成長 6%;而 2024 與 2025 年推出的新產品貢獻了 4,100 萬美元。
Our affordable medicines portfolio includes approximately 270 products across retail, injectables and biosimilars. As Uragan seemed to mention, ML are and the success, excellent supply chain and commercial execution are key strengths driving consistent revenue growth, broadening of our product portfolio, and delivering value to our customers, providers, and patients.
我們的平價藥品產品組合涵蓋約 270 項產品,橫跨零售、注射劑與生物相似藥。如 Uragan 似乎提到的,MLR 與成功的關鍵在於卓越的供應鏈與商業執行;這些是推動營收持續成長、擴大產品組合,並為客戶、醫療提供者與病患創造價值的核心優勢。
In our specialty segment, Q1 revenue of $108 million grew 3%, driven by Cream, which added $9 million, and Unitroid, which added $4 million in the quarter. We're delighted by the market acceptance of Proxha and upcoming payer coverage expansion.
在我們的專科事業部,第一季營收為 1.08 億美元,成長 3%,主要由 Cream 帶動(本季增加 900 萬美元)以及 Unitroid(本季增加 400 萬美元)。我們對 Proxha 的市場接受度以及即將擴大的付款方(payer)給付覆蓋感到非常振奮。
Consequently, we're confident that Craigan will meet or exceed its 2025 revenue goal of $50 million. Q1, after revenues of 172 million grew 6%. A strong growth in the government channel was partially offset by softness in the lower margin distribution channel.
因此,我們有信心 Craigan 將達成或超越其 2025 年 5,000 萬美元的營收目標。第一季,after 營收為 1.72 億美元,成長 6%。政府通路的強勁成長,部分被低毛利分銷通路的疲弱所抵銷。
From the gross margin perspective, we are extremely pleased to report Q1 adjusted gross margins of 43.1%, up 120 basis points year over year.
從毛利率角度來看,我們非常高興地報告第一季調整後毛利率為 43.1%,年增 120 個基點。
The strong margin expansion was driven by favorable product and channel mix, new product launches, and higher efficiencies at the plant level. Q1 is just an EBITDA over$ 170 million through 12% reflecting revenue growth, higher gross margin, and operating expense leverage.
強勁的毛利率擴張主要來自有利的產品與通路組合、新產品上市,以及工廠層級效率提升。第一季調整後 EBITDA 超過 1.70 億美元,成長 12%,反映營收成長、更高毛利率,以及營運費用槓桿效益。
From an EPS perspective, we're pleased to report Q1 adjusted EPS of $0.21, which represents 50% growth driven by higher adjusted EBITDA and lower interest expense. In summary, we're off to a strong start for the year driven by strong execution across a multitude of growth drivers.
從 EPS 角度來看,我們很高興報告第一季調整後 EPS 為 0.21 美元,成長 50%,主要由較高的調整後 EBITDA 與較低的利息費用所帶動。總結而言,在多項成長動能的強勁執行下,我們今年開局表現強勁。
In addition, we continue to strengthen our overall financial position with strong cash flow generation, no near-term debt maturities, and continue to reduce leverage. In 11, gross leverage was further reduced to 4.0 versus 4.1 X at year end 2024, and net leverage remained at 3.9 X.
此外,我們持續透過強勁的現金流創造、近期無到期債務,並持續降低槓桿,來強化整體財務體質。第一季,總槓桿進一步降至 4.0 倍(2024 年底為 4.1 倍),淨槓桿維持在 3.9 倍。
Let me now turn to tariffs and even though it's difficult to quantify precise implications, our team is developing numerous mitigating actions across multiple scenarios. First, our financial forecast already include a modest impact of our current tariff provisions.
接下來談關稅。儘管難以量化其精確影響,我們的團隊正針對多種情境制定多項緩解措施。首先,我們的財務預測已納入目前關稅條款帶來的溫和影響。
Second, we already have a large and growing manufacturing presence in the US which produces 2/3 of our affordable medicines and specialty revenues. The remaining 1/3 mostly comes from R&D operations and imports from the rest of the world are not very meaningful.
第二,我們在美國已擁有龐大且持續成長的製造據點,生產了我們平價藥品與專科業務營收的三分之二。其餘三分之一主要來自研發營運,而自世界其他地區的進口並不顯著。
Third, our teams are taking several mitigating actions to ensure we deliver on our commitments to patients and shareholders. This includes increasing our US-based inventory, secure alternative sources of API. Renegotiating supply agreements.
第三,我們的團隊正採取多項緩解行動,以確保我們能履行對病患與股東的承諾。包括提高美國本土庫存、確保替代的 API(活性藥物成分)來源。重新協商供應協議。
Driving portfolio optimization and other productivity initiatives. Finally, from a long-term perspective, we believe our multiple growth vectors, extensive US manufacturing capabilities, and leading commercial presence position Amneal well in being a top tier growth company.
推動產品組合最佳化及其他生產力提升計畫。最後,從長期角度來看,我們相信多元成長動能、廣泛的美國製造能力,以及領先的商業布局,使 Amneal 具備成為一流成長公司的良好定位。
Finally, we're pleased to affirm our full year 2025 expectations. And as a reminder, we expect total net revenue between $3billion and $3.1 billion, which reflects 7% to 11% upline growth. Adjusted EBITDA between $650million to $675 million reflecting 4% to 8% growth, and adjusted EPS of $0.65 to $0.70 reflecting 12% to 21% growth. I will not throw the call back to Chirag
最後,我們很高興重申 2025 年全年展望。提醒各位,我們預期總淨營收介於 30 億至 31 億美元,反映 7% 至 11% 的年增成長。調整後 EBITDA 介於 6.50 億至 6.75 億美元,反映 4% 至 8% 的成長;調整後 EPS 為 0.65 至 0.70 美元,反映 12% 至 21% 的成長。我現在把電話會議交回給 Chirag
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you. Our performance in Q1 reflects the strength of our diversified business, continued execution of our strategy, and the dedication of our team. We remain confident in our ability to drive sustainable value as we advance in this exciting next chapter of growth. Let's now open the call for questions and answers.
謝謝。我們第一季的表現反映了多元化業務的實力、策略的持續落實,以及團隊的投入。隨著我們邁入這個令人振奮的下一成長篇章,我們仍對推動可持續價值的能力充滿信心。現在開放提問與回答。
Operator
Operator
Thank you. (Operator Instructions) Our first question today comes from David Anelli from Piper Sandler. Your line is now open.
謝謝。(接線員指示) 今天的第一個問題來自 Piper Sandler 的 David Anelli。您的線路已開通。
David Amsellem - Analyst
David Amsellem - Analyst
Hey, good morning and thanks. So I have a couple of questions on biosimilars and generic injectables. First, on biosimilars, can you just give us a refresher on what you expect the 25 contribution, top line contribution. To be particularly interested in how big you think Amneal's could be. I think you in the past have cited it as being about $100 million of contribution, but I just wanted to just level set those expectations for biosimilars for this year.
嗨,早安,謝謝。我有幾個關於生物相似藥與學名注射劑的問題。首先,關於生物相似藥,能否請您再幫我們回顧一下,您預期 2025 年的貢獻、營收端(top line)的貢獻會是多少。我特別想了解您認為 Amneal 的規模可能有多大。我記得你們過去曾提到大約有 1 億美元的貢獻,但我想把今年生物相似藥的預期再校準一下。
And then secondly, you talk about vertical integration regarding your biosimilar business. I guess my question here is when do you think that's going to actually come to pass and How should we be thinking about not just the next couple of years but sort of the next five years as we think about the cadence of new launches and just your overall thoughts on contribution for biosimilars to the top line.
其次,你提到在生物相似藥業務方面的垂直整合。我想我的問題是,你認為這件事何時會真正落地?以及當我們不只看未來幾年、而是看未來五年時,對於新產品上市節奏,以及生物相似藥對營收(top line)貢獻的整體看法,我們應該如何思考?
So that's on biosimilars and then on injectables. I know you've cited shortages, but you've also cited more complex products. I guess if you think about, the business, is there a lean into one versus the other and just help us better understand what you think injectable top line contribution is going to be this year. Thank you.
以上是關於生物相似藥,接著是注射劑。我知道你們提到過短缺,但也提到更複雜的產品。我想如果從業務角度來看,你們會更偏向其中一個方向嗎?也請協助我們更好理解你們認為今年注射劑對營收的貢獻會是多少。謝謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Well thank you David and good morning. Biosymbolism we're in line with what we have said around $150 million to $60 million in total contribution or top line with others being a leading product. You're in the ballpark somewhere between $90million to $100 million. That's what we are driving towards. So that's the current existing products. And then your question on vertical integration. We're looking at options and, we expect to execute on options.
謝謝你,David,早安。生物相似藥方面,我們與先前所說的一致,總貢獻或營收大約在1.5億美元到6,000萬美元之間,其中某個產品是主要產品。你估的區間大概在9,000萬到1億美元之間。這就是我們努力達成的目標。這些是目前既有產品。至於你問的垂直整合,我們正在評估各種選項,也預期會執行其中的選項。
By probably the end of this year, maybe beginning of next year, because we see time as that essence now would like to be very a big player in biosimilars, having the development capabilities, having manufacturing capacity in the United States and in India or other locations in the world, and I have this week, as we said, this is there's a voiding biosimilar.
大概在今年底,或許明年初,因為我們認為時間非常關鍵;我們希望成為生物相似藥領域的重要玩家,具備研發能力、在美國以及印度或全球其他地點的製造產能。而且如我們本週所說,這裡存在一個生物相似藥的空缺。
There's so many products we can work on and when we do look to vertically integrate, we will hope that the partner has a big pipeline and the contribution from a biosimilar business over 5 years and 10 years is going to be very significant. It is the whole, as the value of the biosimilars are huge. The total branded value is $250 to $300 billion and about 100 losing exclusivity over the next 10 years.
我們可以投入的產品非常多;當我們尋求垂直整合時,我們希望合作夥伴擁有龐大的產品管線,而生物相似藥業務在5年與10年的貢獻將會非常顯著。整體而言,生物相似藥的價值非常巨大。整體原研藥的品牌價值約為2,500億到3,000億美元,且未來10年約有100個產品將失去獨占權。
So there is it's. About execution, the market dynamics on the commercial side we believe will work it out over time just like how it worked out in GX, but not exactly like GX because competition here is very less from the supplier standpoint right now we see about somewhere 7 to 10 active companies in the United States that work in the work on the pipeline, serious pipeline.
所以這確實是……關鍵在於執行;在商業端的市場動態,我們相信會隨時間逐步理順,就像學名藥(GX)一樣,但也不會完全相同,因為目前從供應商角度來看競爭要小得多;我們看到在美國大約只有7到10家活躍公司在做、在推進嚴肅的產品管線。
So I know it's a long answer, but it's a very important vertical for us biosimilars to grow, and it's in our wheelhouse. This is what we do. We complex development device combination similar is a very complex manufacturing and great commercialization in the United States and work with partners in the international markets. So it's a great international opportunity. On injectable, I'll pass it over to my younger brother.
我知道回答有點長,但對我們而言,生物相似藥是非常重要、必須成長的垂直領域,而且這正是我們的強項。這就是我們在做的事。我們在複雜開發、裝置組合(device combination)、生物相似藥這些非常複雜的製造,以及在美國的強力商業化方面都有能力,並與國際市場的合作夥伴合作。因此這是一個很好的國際機會。至於注射劑,我把問題交給我弟弟。
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Hi. Good morning. On injectables over the last few years we have expanded our manufacturing footprints and R&D capabilities to work on complex and sometimes we have the capacity which we can work on certain volume products.
嗨。早安。注射劑方面,過去幾年我們擴大了製造據點與研發能力,以投入複雜產品;同時我們也具備產能,可以承接某些量大的產品。
We are very passionate about solving the drug shortage because we believe that drug shortage should not exist. And we have many products where does not affect or impact our ability on the complex development. So we are focusing on both areas. Our complex portfolio is moving very well.
我們非常致力於解決藥品短缺,因為我們相信藥品短缺不應該存在。而且我們有許多產品不會影響或削弱我們在複雜開發方面的能力。因此我們同時聚焦兩個領域。我們的複雜產品組合推進得非常順利。
This year we'll be launching COSA. We have launched, many other 5 5B2 programs. We have a 10-12 pipeline of 552 injectable programs along with microspheress are making good progress. Our liposom is making good progress.
今年我們將推出COSA。我們也已推出許多其他5 5B2專案。我們有10到12個552注射劑專案的管線,同時微球(microspheres)進展良好。我們的脂質體(liposom)也進展良好。
We have deep expertise on drug device combination. We have now infrastructure of about 22 injectable lines with 3 to 4 locations and we are also looking to some manufacturing in the US in coming time also. So we are well positioned on injectables. It's a focused area and it's we're not leaning one over another. We are privatizing both space equally.
我們在藥物—裝置組合方面有深厚專業。目前我們在3到4個地點共建置約22條注射劑產線,並且也在評估未來一段時間在美國進行部分製造。因此我們在注射劑方面具備良好布局。這是重點領域,我們不會偏重其中一個而忽略另一個。我們會同等優先推進兩個領域。
Operator
Operator
Thank you. The next question is from Leszek Sulewski from Truist Securities. Your line is now open.
謝謝。下一個問題來自Truist Securities的Leszek Sulewski。你的線路已開通。
Leszek Sulewski - Analyst
Leszek Sulewski - Analyst
Good morning. Thank you for taking my questions. First, I wanted to focus on (Ascare). How exposes AFCA to the federal government costs, if any, how are you positioning this business in the current environment, I guess. And then second, on, are you seeing any sort of FDA delays, whether it's on approvals or feedbacks on the generics front? and any sort of I guess initial potential from facility site visits delays as well.
早安。謝謝讓我提問。首先,我想聚焦在(Ascare)。AFCA在多大程度上會暴露於聯邦政府的成本削減(若有的話)?在目前環境下你們如何定位這項業務?其次,在學名藥方面,你們是否看到FDA有任何延遲,不論是核准或回饋?以及我想也包括設施現場查核(site visits)可能出現的延遲?
And then second, just kind of talk to us about the ongoing partnership selection and reckon X. I know you've identified EU and South America and Canada, but perhaps we should give us a little bit of timeline on other parts and then specifically in with your timeline to launch in India and the opportunity there. Thank you.
另外,請談談Cracks on XUS持續進行的合作夥伴遴選與推進情況。我知道你們已鎖定歐盟、南美與加拿大,但也許可以提供其他地區的大致時程;並且特別談談你們在印度的上市時程與當地機會。謝謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Well thank you Les and good morning. So VA this federal cuts do not apply to the pharmaceuticals. VA is actually expanding $18 million lives, so, and more, our veterans are becoming older, so more prescription drugs, so we see volume growth actually in VA DOD, so we do not see any issue there.
謝謝你,Les,早安。關於VA,這些聯邦削減不適用於藥品。VA其實正在擴張到1,800萬名受益人,而且我們的退伍軍人年齡愈來愈大,因此處方藥需求增加;所以我們在VA與DOD其實看到的是量的成長,並不認為那裡會有問題。
The question on FTA, we haven't seen any delays from FDA at this point, so no issue there. And then Cracks on XUS, we have the partnership in place for Canada. Latin America, Europe, and now we just signed Southeast Asia. India, we're going to market by ourselves.
至於FDA,我們目前沒有看到任何延遲,所以沒有問題。再來Cracks on XUS方面,我們已在加拿大建立合作夥伴關係。拉丁美洲、歐洲,以及我們剛簽下東南亞。印度方面,我們將自行進入市場。
Europe is the largest, I mean the largest market size will be for us, and partners doing a phase 4 additional small phaco for European requirements to get a proper reimbursement. And then India, we haven't gauged the exact market size, but it's a much needed all over the world. Only I is available for the last 30-40 years, and these patients really will benefit from taxon. And looking at China and Japan that those talks are going on right now.
歐洲將是我們最大的市場,也就是對我們而言市場規模最大;合作夥伴正在依歐洲要求進行第四期(phase 4)額外的小型藥物經濟學(phaco)研究,以取得適當的給付(reimbursement)。至於印度,我們尚未精確評估市場規模,但這在全球都是高度需要的。過去30到40年只有I可用,而這些病患將能從taxon中獲益良多。另外,中國與日本的洽談也正在進行中。
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Let's just to add one thing on FDA, none of our gold dates have been impacted. All of our products are progressing well, and it's part of the Gro user fee. Inspection plus all plants are approved and in a very good standing. That also benefits us from any potential delays, but as of today we have not seen any delays on our application or the bold.
再補充一點關於 FDA 的情況,我們的任何黃金日期都沒有受到影響。我們所有產品的進展都很順利,這也是 Gro 使用者費用的一部分。稽查加上所有工廠都已獲核准,且狀況非常良好。這也讓我們能受益於避免任何潛在延遲,但截至今天,我們尚未在申請或該項目上看到任何延遲。
Operator
Operator
Thank you. And the next question is from Chris Schott from JP Morgan. Your line is now open.
謝謝。下一個問題來自摩根大通的 Chris Schott。您的線路已開通。
Chris Schott - Analyst
Chris Schott - Analyst
Great, thanks so much for the questions. I said maybe to start with a two parter on tariffs. I know you have a different manufacturing footprint versus peers. So if we were to see tariffs applied to pharmaceuticals, do you see an opportunity to further leverage your US manufacturing footprint and just talk a little bit about what type of capacity you'd have to utilize if in fact we did see tariffs applied?
很好,謝謝你們回答問題。我想先從關稅的兩個問題開始。我知道相較同業,你們的製造佈局不同。所以如果我們看到藥品被加徵關稅,你們是否看到進一步運用你們美國製造佈局的機會?也請談談若真的加徵關稅,你們可動用的產能大概會是什麼樣的規模?
My second question on the tariff front was for some of the products that are potentially exposed to tariffs and thinking about the affordable medicines portfolio, what is the ability to increase price on some of these products to offset some of those pressures, or is the goal of ENeil more to pivot the manufacturing to either your own capacity or third parties to avoid tariffs on those and then maybe one follow up after that.
我第二個關於關稅的問題是:對於一些可能暴露於關稅的產品,並以平價藥品(affordable medicines)產品組合來看,這些產品在多大程度上能透過提價來抵消部分壓力?還是 ENeil 的目標更偏向把製造轉移到你們自有產能或第三方,以避免這些產品被課關稅?之後我再追問一個問題。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Oh thank you, Chris. So if tariffs were to The common on genetics, pharmaceuticals, leveraging over US manufacturing footprint, we have, additional capacity. We have one ideal plant for a long time now, which we would restart if economically viable.
喔,謝謝你,Chris。所以如果關稅真的——一般來說若對學名藥、藥品加徵關稅,並利用我們在美國的製造佈局,我們確實有額外產能。我們有一座閒置工廠已經有一段時間了,如果在經濟上可行,我們會重啟。
We still have to do that. There is a long term economically viable, about $8billion to $10 billion more units of solids of liquid manufacturing, topical manufacturing, transdermal manufacturing we can produce in the United States.
我們仍需要去做這件事。從長期、經濟可行的角度來看,我們在美國可生產約 80 億到 100 億個單位的固體、液體製劑產能,還包括外用製劑與透皮製劑的製造。
So we would, we are already set to go, but it has to be economically viable and your question on, increase in prices, obviously, look, if there are tariff related increases. We would work with our big customers, they have to participate in that, which is the CVS and UnitedHealth and Cigna. These are large companies, and there is some positive indication from the customers that they would.
所以我們已經準備就緒,但前提是必須在經濟上可行。至於你提到的提價問題,顯然,如果出現與關稅相關的成本上升,我們會與我們的大客戶合作,他們必須共同分擔,像是 CVS、UnitedHealth 和 Cigna。這些都是大型公司,而且從客戶端我們看到一些正面的訊號,表示他們願意。
They would partner in if something has to happen because we, the last thing we want is any kind of discontinuation or shortages. So that's the news so far. Thank you, Chris.
如果真的需要採取行動,他們會願意合作,因為我們最不希望看到任何停供或短缺。目前就是這些最新進展。謝謝你,Chris。
Chris Schott - Analyst
Chris Schott - Analyst
Great and just as a follow up on Cork looking at scripts. I mean, obviously great trends so far. It seems like we're seeing very little cannibalization from Rotari as we've seen the ramp. I know that hasn't been the focus, but as we get closer to that Rotari Lloe, is there an opportunity to maybe accelerate some of the conversion of those patients ahead of generic entry, or is the focus more on just the broader market here? Thanks so much.
很好,另外追問一下關於 Cork、看處方量(scripts)。我的意思是,到目前為止趨勢顯然非常好。看起來隨著 Rotari 的放量,我們看到的自我侵蝕(cannibalization)非常少。我知道這不是重點,但當我們更接近 Rotari Lloe 時,是否有機會在學名藥進入前,加速把那些病患提前轉換過來?還是重點仍然是更廣泛的市場?非常感謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Yeah, Chris, so we focus, as we have said from the beginning, it's a broader market. It's a huge market, almost 650,000 patients we could potentially be on Creon reached up to 40,000. We are already at a run rate of 20,000 patients now, and by year end we'll have 25,000 and then next year we could reach easily double that or more.
是的,Chris,我們的重點如同一開始所說,是更廣泛的市場。這是一個非常大的市場,潛在大約有 65 萬名病患可使用 Creon,目前我們已觸及到 4 萬名。我們現在的運行速度已達 2 萬名病患,到年底會到 2.5 萬名,明年我們很容易就能達到兩倍或更多。
So 80% of that is coming from the new patient IR, which was our goal. And, as I pointed out, the KOL by himself took terri over the years, now taking Creon, seeing a huge impact. So as The patients are many of these MDS already have started shifting their patient to exon because it's just a much better drug than Reta.
其中 80% 來自新病患 IR,這正是我們的目標。而且如我提到的,那位 KOL 多年來一直使用 terri,現在改用 Creon,看到非常大的影響。因此,許多 MDS 的醫師其實已經開始把病患轉到 exon,因為它就是比 Reta 好得多的藥。
So we would see both, but we have, we're not doing anything particular. We don't need to move or convert aggressively from Reri toxon at all.
所以兩者我們都會看到,但我們沒有做任何特別的動作。我們完全不需要從 Reri 轉到 exon 做任何激進的轉換。
Chris Schott - Analyst
Chris Schott - Analyst
Thanks so much.
非常感謝。
Anthony Dimeo - Head of Investor Relations
Anthony Dimeo - Head of Investor Relations
Thank you, Chris.
謝謝你,Chris。
Operator
Operator
Thank you. We have no further questions, so I'd like to hand back to Chirag for concluding.
謝謝。我們沒有其他問題了,所以我想把時間交回給 Chirag 做結語。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Well, thank you very much. We're so excited and I'm new and we wish everybody a great weekend. Thank you, everyone.
好的,非常感謝。我們非常興奮,我也是新加入的,祝大家週末愉快。謝謝各位。
Operator
Operator
Thank you. This does conclude today's call. You may now disconnect your lines and enjoy the rest of your day. Thank you.
謝謝。今天的電話會議到此結束。您現在可以掛斷線路,祝您今天剩餘時間愉快。謝謝。